Villanueva C, Miñana J, Ortiz J, Gallego A, Soriano G, Torras X, Sáinz S, Boadas J, Cussó X, Guarner C, Balanzó J
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
N Engl J Med. 2001 Aug 30;345(9):647-55. doi: 10.1056/NEJMoa003223.
After an episode of acute bleeding from esophageal varices, patients are at high risk for recurrent bleeding and death. We compared two treatments to prevent recurrent bleeding--endoscopic ligation and combined medical therapy with nadolol and isosorbide mononitrate.
We randomly assigned 144 patients with cirrhosis who were hospitalized with esophageal variceal bleeding to receive treatment with endoscopic ligation (72 patients) or the combined medical therapy (72 patients). Sessions of ligation were repeated every two to three weeks until the varices were eradicated. The initial dose of nadolol was 80 mg orally once daily, with adjustment according to the resting heart rate; isosorbide mononitrate was given in increasing doses, beginning at 20 mg once a day at bed time and rising over the course of one week to 40 mg orally twice a day, unless side effects occurred. The primary end points were recurrent bleeding, complications, and death.
The median follow-up period was 21 months. A total of 35 patients in the ligation group and 24 in the medication group had recurrent bleeding. The probability of recurrence was lower in the medication group, both for all episodes related to portal hypertension (P=0.04) and for recurrent variceal bleeding (P=0.04). There were major complications in nine patients treated with ligation (seven had bleeding esophageal ulcers and two had aspiration pneumonia) and two treated with medication (both had bradycardia and dyspnea) (P=0.05). Thirty patients in the ligation group died, as did 23 patients in the medication group (P=0.52). The probability of recurrent bleeding was lower for patients with a hemodynamic response to therapy, defined as a decrease in the hepatic venous pressure gradient of more than 20 percent from the base-line value or to less than 12 mm Hg (18 percent, vs. 54 percent in patients with no hemodynamic response at one year; P<0.001), and the probability of survival was higher (94 percent vs. 78 percent at one year, P=0.02).
Combined therapy with nadolol and isosorbide mononitrate is more effective than endoscopic ligation for the prevention of recurrent bleeding and is associated with a lower rate of major complications. A hemodynamic response to treatment is associated with a better long-term prognosis.
食管静脉曲张急性出血发作后,患者再次出血和死亡风险很高。我们比较了两种预防再次出血的治疗方法——内镜下套扎术以及纳多洛尔与单硝酸异山梨酯联合药物治疗。
我们将144例因食管静脉曲张出血而住院的肝硬化患者随机分组,分别接受内镜下套扎术治疗(72例患者)或联合药物治疗(72例患者)。每两至三周重复进行套扎术,直至静脉曲张消除。纳多洛尔初始剂量为口服80毫克,每日一次,根据静息心率调整剂量;单硝酸异山梨酯剂量递增,开始时为每日20毫克,睡前服用,一周内逐渐增至每日两次,每次40毫克口服,除非出现副作用。主要终点为再次出血、并发症和死亡。
中位随访期为21个月。套扎组共有35例患者再次出血,药物治疗组有24例。药物治疗组的复发概率较低,无论是与门静脉高压相关的所有发作(P = 0.04)还是复发性静脉曲张出血(P = 0.04)。接受套扎术治疗的9例患者出现严重并发症(7例有食管溃疡出血,2例有吸入性肺炎),接受药物治疗的2例患者出现严重并发症(均有心动过缓和呼吸困难)(P = 0.05)。套扎组30例患者死亡,药物治疗组23例患者死亡(P = 0.52)。对治疗有血流动力学反应的患者再次出血概率较低,血流动力学反应定义为肝静脉压力梯度较基线值降低超过20%或降至低于12毫米汞柱(一年时为18%,无血流动力学反应的患者为54%;P<0.001),生存概率较高(一年时为94%对78%,P = 0.02)。
纳多洛尔与单硝酸异山梨酯联合治疗在预防再次出血方面比内镜下套扎术更有效,且严重并发症发生率较低。对治疗的血流动力学反应与更好的长期预后相关。